Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are anticipating strong performance driven by the strong demand of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential challenges from rising